Rui Pedro Galão

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8793266/publications.pdf

Version: 2024-02-01

13 papers 2,146 citations

1051969 10 h-index 13 g-index

27 all docs

27 docs citations

times ranked

27

6674 citing authors

#	Article	IF	CITATIONS
1	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. Clinical Microbiology and Infection, 2022, 28, 93-100.	2.8	21
2	TRIM25 and ZAP target the Ebola virus ribonucleoprotein complex to mediate interferon-induced restriction. PLoS Pathogens, 2022, 18, e1010530.	2.1	14
3	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. PLoS ONE, 2021, 16, e0249791.	1.1	6
4	The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2. Journal of Virology, 2021, 95, .	1.5	121
5	More than the Eye Can See: Shedding New Light on SARS-CoV-2 Lateral Flow Device-Based Immunoassays. ACS Applied Materials & Interfaces, 2021, 13, 25694-25700.	4.0	10
6	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity, 2021, 54, 1276-1289.e6.	6.6	112
7	Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. Lancet Microbe, The, 2021, 2, e461-e471.	3.4	109
8	Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation. PLoS ONE, 2021, 16, e0256813.	1.1	23
9	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nature Microbiology, 2021, 6, 1433-1442.	5.9	94
10	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology, 2020, 5, 1598-1607.	5.9	1,115
11	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathogens, 2020, 16, e1008817.	2.1	105
12	Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. Analyst, The, 2020, 145, 5638-5646.	1.7	26
13	KHNYN is essential for the zinc finger antiviral protein (ZAP) to restrict HIV-1 containing clustered CpG dinucleotides. ELife, 2019, 8, .	2.8	98